These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
292 related articles for article (PubMed ID: 18521528)
1. The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations. Balemans W; Piters E; Cleiren E; Ai M; Van Wesenbeeck L; Warman ML; Van Hul W Calcif Tissue Int; 2008 Jun; 82(6):445-53. PubMed ID: 18521528 [TBL] [Abstract][Full Text] [Related]
2. Structure-based mutation analysis shows the importance of LRP5 beta-propeller 1 in modulating Dkk1-mediated inhibition of Wnt signaling. Bhat BM; Allen KM; Liu W; Graham J; Morales A; Anisowicz A; Lam HS; McCauley C; Coleburn V; Cain M; Fortier E; Bhat RA; Bex FJ; Yaworsky PJ Gene; 2007 Apr; 391(1-2):103-12. PubMed ID: 17276019 [TBL] [Abstract][Full Text] [Related]
3. Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling. Ai M; Holmen SL; Van Hul W; Williams BO; Warman ML Mol Cell Biol; 2005 Jun; 25(12):4946-55. PubMed ID: 15923613 [TBL] [Abstract][Full Text] [Related]
4. Analysis of association of LRP5, LRP6, SOST, DKK1, and CTNNB1 genes with bone mineral density in a Slovenian population. Mencej-Bedrac S; Prezelj J; Kocjan T; Komadina R; Marc J Calcif Tissue Int; 2009 Dec; 85(6):501-6. PubMed ID: 19898734 [TBL] [Abstract][Full Text] [Related]
5. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Qiang YW; Barlogie B; Rudikoff S; Shaughnessy JD Bone; 2008 Apr; 42(4):669-80. PubMed ID: 18294945 [TBL] [Abstract][Full Text] [Related]
6. NMR structure of the Wnt modulator protein Sclerostin. Weidauer SE; Schmieder P; Beerbaum M; Schmitz W; Oschkinat H; Mueller TD Biochem Biophys Res Commun; 2009 Feb; 380(1):160-5. PubMed ID: 19166819 [TBL] [Abstract][Full Text] [Related]
7. Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo. Choi HY; Dieckmann M; Herz J; Niemeier A PLoS One; 2009 Nov; 4(11):e7930. PubMed ID: 19936252 [TBL] [Abstract][Full Text] [Related]
8. Expression, purification and functional characterization of Wnt signaling co-receptors LRP5 and LRP6. Fleury D; Vayssiere B; Touitou R; Gillard C; Lebhar H; Rawadi G; Mollat P Protein Expr Purif; 2010 Mar; 70(1):39-47. PubMed ID: 19716419 [TBL] [Abstract][Full Text] [Related]
9. Novel LRP5 missense mutation in a patient with a high bone mass phenotype results in decreased DKK1-mediated inhibition of Wnt signaling. Balemans W; Devogelaer JP; Cleiren E; Piters E; Caussin E; Van Hul W J Bone Miner Res; 2007 May; 22(5):708-16. PubMed ID: 17295608 [TBL] [Abstract][Full Text] [Related]
10. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. Li X; Zhang Y; Kang H; Liu W; Liu P; Zhang J; Harris SE; Wu D J Biol Chem; 2005 May; 280(20):19883-7. PubMed ID: 15778503 [TBL] [Abstract][Full Text] [Related]
11. Wnt antagonists bind through a short peptide to the first β-propeller domain of LRP5/6. Bourhis E; Wang W; Tam C; Hwang J; Zhang Y; Spittler D; Huang OW; Gong Y; Estevez A; Zilberleyb I; Rouge L; Chiu C; Wu Y; Costa M; Hannoush RN; Franke Y; Cochran AG Structure; 2011 Oct; 19(10):1433-42. PubMed ID: 21944579 [TBL] [Abstract][Full Text] [Related]
12. Wnt signaling: a key regulator of bone mass. Baron R; Rawadi G; Roman-Roman S Curr Top Dev Biol; 2006; 76():103-27. PubMed ID: 17118265 [TBL] [Abstract][Full Text] [Related]
13. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Li J; Sarosi I; Cattley RC; Pretorius J; Asuncion F; Grisanti M; Morony S; Adamu S; Geng Z; Qiu W; Kostenuik P; Lacey DL; Simonet WS; Bolon B; Qian X; Shalhoub V; Ominsky MS; Zhu Ke H; Li X; Richards WG Bone; 2006 Oct; 39(4):754-66. PubMed ID: 16730481 [TBL] [Abstract][Full Text] [Related]
14. Lrp5 and bone formation : A serotonin-dependent pathway. Yadav VK; Ducy P Ann N Y Acad Sci; 2010 Mar; 1192():103-9. PubMed ID: 20392224 [TBL] [Abstract][Full Text] [Related]
15. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Li ZG; Yang J; Vazquez ES; Rose D; Vakar-Lopez F; Mathew P; Lopez A; Logothetis CJ; Lin SH; Navone NM Oncogene; 2008 Jan; 27(5):596-603. PubMed ID: 17700537 [TBL] [Abstract][Full Text] [Related]
16. High Bone Mass-Causing Mutant LRP5 Receptors Are Resistant to Endogenous Inhibitors In Vivo. Niziolek PJ; MacDonald BT; Kedlaya R; Zhang M; Bellido T; He X; Warman ML; Robling AG J Bone Miner Res; 2015 Oct; 30(10):1822-30. PubMed ID: 25808845 [TBL] [Abstract][Full Text] [Related]
17. Mesd is a universal inhibitor of Wnt coreceptors LRP5 and LRP6 and blocks Wnt/beta-catenin signaling in cancer cells. Lu W; Liu CC; Thottassery JV; Bu G; Li Y Biochemistry; 2010 Jun; 49(22):4635-43. PubMed ID: 20446724 [TBL] [Abstract][Full Text] [Related]
18. Expression, purification and characterization of murine Dkk1 protein. Fleury D; Gillard C; Lebhar H; Vayssière B; Touitou R; Rawadi G; Mollat P Protein Expr Purif; 2008 Jul; 60(1):74-81. PubMed ID: 18456511 [TBL] [Abstract][Full Text] [Related]
19. LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. Semenov MV; He X J Biol Chem; 2006 Dec; 281(50):38276-84. PubMed ID: 17052975 [TBL] [Abstract][Full Text] [Related]
20. The high bone mass family--the role of Wnt/Lrp5 signaling in the regulation of bone mass. Johnson ML J Musculoskelet Neuronal Interact; 2004 Jun; 4(2):135-8. PubMed ID: 15615112 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]